AG百家乐大转轮-AG百家乐导航_怎么看百家乐走势_全讯网官网 (中国)·官方网站

Research News

Nature Reviews Drug Discovery: targeting cancer-associated fibroblasts

Share
  • Updated: Dec 24, 2018
  • Written:
  • Edited:
Source: Sun Yat-sen Memorial Hospital
Written by: Xueman Chen
Edited by: Wang Dongmei

Recently, a Review Article entitled “Turning foes to friends: targeting cancer-associated fibroblasts” was published online in Nature Reviews Drug Discovery (IF 2018=50.17)1. Professor Erwei Song, President of Sun Yat-sen Memorial Hospital, Sun Yat-sen University, is the corresponding author, and Xueman Chen, a PhD student from his team, is the first author.

Current paradigms of cancer-centric therapeutics are usually not sufficient to eradicate the malignancy, as the cancer stroma may prompt tumor relapse and therapeutic resistance. In the past decade, a burst of knowledge on how the tumor microenvironment (TME) interacts with tumor cells has urged studies on a new cancer treatment paradigm: targeting the tumor stroma. Among all the stromal cells that populate the TME, cancer-associated fibroblasts (CAFs) are the most abundant and are critically involved in cancer progression, which render them as conspicuous stromal targets in many, if not all, solid tumors. However, without unequivocal cell-surface markers, live-cell sorting for functional and mechanistic studies on CAFs in vitro and targeting therapies towards CAFs in vivo are greatly hindered.

It is noteworthy that a previous research from Prof. Erwei Song’s team revealed CD10 and GPR77 as two specific cell-surface makers for a novel pro-tumorigenic CAF subset involved in cancer stemness and chemoresistance2. More importantly, GPR77 is a functional marker which can be directly targeted for in vivo CAF depletion. The restoration of chemosensitivity of tumor cells upon GPR77 blockade further suggests the remarkable therapeutic value of such a precise CAF-targeted strategy for cancers.


Accumulated molecular characterization of CAFs not only deepens our insights into their phenotypic heterogeneity and functional diversity, but also brings CAF-targeting therapies for cancer treatment onto the agenda. However, translating the basic research into clinical practice takes tremendous efforts and is extremely time-consuming, which makes it an urgent need for therapists and drug developers to comprehensively recognize the functional significance and molecular mechanisms of CAFs in cancers.

In this Review, Prof. Song’s team presented a full-scale overview regarding the current understanding of the hallmarks, biology and heterogeneity of CAFs, highlighting the CAF-centered intercellular crosstalk within the TME, and discussed multipronged functions of CAFs in tumor initiation, progression, metastasis and resistance to anticancer therapies. Prof. Song’s team also elaborated on the potential therapeutic strategies targeting CAFs, with an aim to accelerate the leap from bench to bedside.


References
1.  Chen, X. & Song, E. Turning foes to friends: targeting cancer-associated fibroblasts. Nature Reviews Drug Discovery (2018).
2.  Su, S., et al. CD10(+)GPR77(+) Cancer-Associated Fibroblasts Promote Cancer Formation and Chemoresistance by Sustaining Cancer Stemness. Cell (2018).

Link to the review article: www.nature.com/articles/s41573-018-0004-1
TOP
网上的百家乐是真是假| 百家乐官网输惨了| 棋牌娱乐网,| 百家乐官网tt娱乐平台| 百家乐官网最大的赌局| 大发888客服电话 导航| 做生意的十大风水禁忌| 宜兰市| 最好的百家乐博彩公司| 百家乐官网有秘技吗| 百家乐游戏平台架设| 全讯网.com| 金花百家乐官网的玩法技巧和规则 | 百家乐官网专用台布| 百家乐api| 百家乐官网游戏接口| 大发888扑克官方下载| 百家乐官网平注法到65688| 德州扑克发牌顺序| 澳门百家乐的公式| 百家乐官网破解仪| 百家乐官网招商用语| 百家乐与龙虎斗怎么玩| 百家乐官网路子| 娱乐城送| 百家乐赌博详解| 鼎龙百家乐官网的玩法技巧和规则 | 百家乐官网科学打法| 老江死了| 百家乐怎么看大小| 百家乐官网乐赌| 波音代理| 舟山星空棋牌游戏大厅下载| 百家乐香港六合彩| 百家乐赌术揭秘| 百家乐官网里靴是什么意识| 大发888优惠码| 太子百家乐的玩法技巧和规则 | 订做百家乐官网桌子| 百家乐官网怎么赢对子| A8娱乐城|